Stifel Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has initiated coverage on ORIC Pharmaceuticals with a Buy rating and set a price target of $20.
September 06, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel has initiated coverage on ORIC Pharmaceuticals with a Buy rating and a price target of $20, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $20 by Stifel suggests a positive sentiment towards ORIC Pharmaceuticals. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100